Evidence map›Paper›PMID 30251731›Full record

ArticleSaudi medical journal2018

Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients.

Haider H Zalzala, Galawish A Abdullah, Mohammed Y Abbas, Hyam R Mohammedsalih, Batool M Mahdi

Open access · diamondAbstract read
In one paragraph

Article in Saudi medical journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Haider H ZalzalaDepartment of Microbiology & Immunology, HLA Typing Research Unit, Al-kindy College of Medicine, University of Baghdad, Baghdad, Iraq. E-mail. haiderhashim@kmc.uobaghdad.edu.iq.
Galawish A Abdullah
Mohammed Y Abbas
Hyam R Mohammedsalih
Batool M Mahdi
University of Baghdad · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the role of Human leukocyte antigen (HLA) Class II DRB1 in susceptibility to psoriasis in Iraqi patients.

methodsA cross-sectional comparative study including 40 patients with psoriasis attending the Department of Dermatology, Al-Kindy teaching hospital in Baghdad, Iraq, between September 2013-2015. Patient selection was carried out by the dermatologists. Ninety healthy individuals were included in the study. Human leukocyte antigen genotyping was carried out by the sequence specific oligonucleotide (SSO) method using Auto LiPA 48 (Innogenetics, Belgium) in the HLA typing research unit of the Al-Kindy College of Medicine, Baghdad, Iraq.

resultsThere is an increased frequency of HLA-DRB1*0102, *0306 in psoriatic patients with psoriasis p-values=0.001, confidence interval(CI)=2.492-37.487 and odds ratio(OR)=9.666. Human leukocyte antigen-DRB1*1101 is significantly associated with plaque-type psoriasis with p=0.0434, CI=1.04-1.69, and OR=4.2. Human leukocyte antigen-DRB1*0102 is significantly associated with other types of psoriasis with p=0.018, CI=0.0223-0.701, and OR=0.125.

conclusionHuman leukocyte antigen-DRB1*0102 and *0306 are significantly associated with psoriasis. Human leukocyte antigen-DRB1*1101 is significantly associated with plaque-type psoriasis. Human leukocyte antigen-DRB1*0102 is significantly associated with other types of psoriasis rather than plaque-type psoriasis.

Indexed as

AdolescentAdultCase-Control StudiesChildChild, PreschoolCross-Sectional StudiesFemaleGenetic Predisposition to DiseaseGenotypeHLA-DRB1 ChainsHumansIraqMaleMiddle AgedPolymerase Chain ReactionPsoriasisHLA-DRB1 Chains

Identifiers

PMID30251731
PMCPMC6201012
OpenAlexW2890990570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.